BridgeMD
New treatment option for Infection Catheter-Related
Official title Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement
ClinicalTrials.gov ID: NCT06814223
What this study is testing
What is • Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA?
• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for infection catheter-related.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to determine if prophylactic antibiotic treatment can reduce the incidence of early catheter-related infections in hemodialysis patients at high risk, including those with femoral catheter placement, atrial fibrillation, or heart failure. The main questions it aims to answer are: 1.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Hemodialysis patients scheduled for new tunneled catheter placement or replacement of an existing tunneled catheter.
- Prior diagnosis of at least one of the following conditions:
- Atrial fibrillation
- Heart failure
- Femoral tunneled catheter
You likely can't join if
- Hemodialysis patients unable to provide informed consent and requiring a legal guardian.
- Patients undergoing prolonged antibiotic therapy prior to tunneled catheter insertion.
See the full eligibility criteria
- Hemodialysis patients scheduled for new tunneled catheter placement or replacement of an existing tunneled catheter.
- Prior diagnosis of at least one of the following conditions:
- Atrial fibrillation
- Heart failure
- Femoral tunneled catheter
- Patients who have signed informed consent to participate in the study.
- Hemodialysis patients unable to provide informed consent and requiring a legal guardian.
- Patients undergoing prolonged antibiotic therapy prior to tunneled catheter insertion.
The study team makes the final eligibility decision.
Where it's taking place
- Nahariya, Israel, Israel
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nahariya, Israel, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.